NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB: PLRS - News) today announced that it has been chosen to present at the annual meeting of the American Society of Hematology on December 10th in Orlando, Florida. Hematology experts from around the world will gather to discuss the latest developments in their field. Pluristem will present how it has overcome the major barrier resulting from pre-selection and separation of cord blood early hematopoietic stem cells (HSC), and their breakthrough process that improves engraftment of Umbilical Cord Blood when treating severe blood disorders.

The current methodologies used in HSC expansion protocols apply an enrichment stage of rare subpopulation source cells defined as CD34 positive cells. These CD34 cells are pre-selected from a large and mixed population of mononuclear cells. This process results in a substantial loss of source cells and targets a cell population that may not represent the earliest extractable population of HSC.